newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023KIN-8741, a highly selective c-MET inhibitor designed to